The last financial report show the Infusion business was break-even so selling part of the "farm" for $6.5M isn't a negative, they need to re-direct their focus on ADAPT and in particular TAVR (currently it's MC is lower than most ASX listed start-up biotech stock......)
The last financial report show the Infusion business was...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.300(2.40%) |
Mkt cap ! $262.3M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.50 | $11.89 | $101.9K | 8.268K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309 | $12.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 259 | 4 |
View Market Depth
| Last trade - 12.16pm 30/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |